Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924288 | 1.00 | KCNH2 (0.41) | KCNH2TLR8TLR7EGFRKDR | |
| SCHEMBL30076081 | 1.00 | KCNH2 (0.41) | KCNH2TLR8TLR7EGFRKDR | |
| SCHEMBL19935525 | 0.88 | KCNH2 (0.56) | KCNH2TLR8TLR7EGFRKDR | |
| SCHEMBL30076138 | 0.88 | KCNH2 (0.55) | KCNH2TLR8TLR7 | |
| SCHEMBL19924219 | 0.88 | KCNH2 (0.55) | KCNH2TLR8TLR7 | |
| SCHEMBL19924220 | 0.88 | KCNH2 (0.55) | KCNH2TLR8TLR7 | |
| SCHEMBL19935595 | 0.83 | TLR8 (0.54) | KCNH2TLR8TLR7ALDH1A1 | |
| SCHEMBL19998638 | 0.81 | KCNH2 (0.39) | KCNH2TLR8TLR7ALDH1A1 | |
| SCHEMBL19924210 | 0.77 | PDE4A (0.39) | TLR8TLR7ALDH1A1 | |
| SCHEMBL19924213 | 0.77 | PDE4A (0.39) | TLR8TLR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522570-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240254091-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-109923106-B | toll-like receptor modulator compounds | 吉利德科学公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3507276-B1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3507276-B1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11124487-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124487-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-10370342-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370342-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2018045144-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180065938-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065938-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4399/4885TLR8 1/4885TLR7 9/4885 |
| US-10370342-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | KCNH2 4399/4885TLR8 1/4885TLR7 9/4885 |
| US-11124487-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | KCNH2 4399/4885TLR8 1/4885TLR7 9/4885 |
| US-20240254091-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4399/4885TLR8 1/4885TLR7 9/4885 |
| US-20180065938-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4399/4885TLR8 1/4885TLR7 9/4885 |
| US-11827609-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | KCNH2 4399/4885TLR8 1/4885TLR7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.